Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 11—November 2016
CME ACTIVITY - Research

Multidrug-Resistant Corynebacterium striatum Associated with Increased Use of Parenteral Antimicrobial Drugs

William O. Hahn, Brian J. Werth, Susan M. Butler-Wu1, and Robert M. RakitaComments to Author 
Author affiliations: Author affiliation: University of Washington, Seattle, Washington, USA

Main Article

Table

Drug resistance patterns for Corynebacterium striatum isolates from patients at the University of Washington Medical Center, Seattle, Washington, USA, 2005–2014*

Characteristic Penicillin, n = 121 Tetracycline, n = 119 Clindamycin, n = 103 Erythromycin, n = 72 Ciprofloxacin, n = 119 Vancomycin, n = 120
Mean MIC 18 34 209 66 51 0.6
Median MIC 8 32 256 16 32 0.5
MIC range 0.125–256 0.125–256 0.25–256 0.25–256 0.125–256 0.125–1
MIC50 8 32 256 16 32 0.5
MIC90 32 64 256 256 32 1

*Resistance is defined as per Clinical and Laboratory Standards Institute Guidelines (20). Values are in milligrams/liter. MIC50, concentration required to inhibit 50% of bacteria; MIC90, concentration required to inhibit 90% of bacteria.

Main Article

References
  1. Gavin  SE, Leonard  RB, Briselden  AM, Coyle  MB. Evaluation of the rapid CORYNE identification system for Corynebacterium species and other coryneforms. J Clin Microbiol. 1992;30:1692–5.PubMedGoogle Scholar
  2. Fernández Guerrero ML, Molins A, Rey M, Romero J, Gadea I. Multidrug-resistant Corynebacterium successfully treated with daptomycin. Int J Antimicrob Agents. 2012;40:373–4 .DOIGoogle Scholar
  3. Rufael  DW, Cohn  SE. Native valve endocarditis due to Corynebacterium striatum: case report and review. Clin Infect Dis. 1994;19:1054–61.DOIPubMedGoogle Scholar
  4. Mashavi  M, Soifer  E, Harpaz  D, Beigel  Y. First report of prosthetic mitral valve endocarditis due to Corynebacterium striatum: Successful medical treatment. Case report and literature review. J Infect. 2006;52:e139–41.DOIPubMedGoogle Scholar
  5. Marull  J, Casares  PA. Nosocomial valve endocarditis due to corynebacterium striatum: a case report. Cases J. 2008;1:388.DOIPubMedGoogle Scholar
  6. Melero-Bascones  M, Muñoz  P, Rodríguez-Créixems  M, Bouza  E. Corynebacterium striatum: an undescribed agent of pacemaker-related endocarditis. Clin Infect Dis. 1996;22:576–7.DOIPubMedGoogle Scholar
  7. Tattevin  P, Crémieux  AC, Muller-Serieys  C, Carbon  C. Native valve endocarditis due to Corynebacterium striatum: first reported case of medical treatment alone. Clin Infect Dis. 1996;23:1330–1.DOIPubMedGoogle Scholar
  8. Martínez-Martínez  L, Suárez  AI, Rodríguez-Baño  J, Bernard  K, Muniáin  MA. Clinical significance of Corynebacterium striatum isolated from human samples. Clin Microbiol Infect. 1997;3:634–9.DOIPubMedGoogle Scholar
  9. Lagrou  K, Verhaegen  J, Janssens  M, Wauters  G, Verbist  L. Prospective study of catalase-positive coryneform organisms in clinical specimens: identification, clinical relevance, and antibiotic susceptibility. Diagn Microbiol Infect Dis. 1998;30:7–15.DOIPubMedGoogle Scholar
  10. Soriano  F, Zapardiel  J, Nieto  E. Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother. 1995;39:208–14.DOIPubMedGoogle Scholar
  11. Martínez-Martínez  L, Pascual  A, Bernard  K, Suárez  AI. Antimicrobial susceptibility pattern of Corynebacterium striatum. Antimicrob Agents Chemother. 1996;40:2671–2.PubMedGoogle Scholar
  12. Yoo  G, Kim  J, Uh  Y, Lee  HG, Hwang  GY, Yoon  KJ. Multidrug-resistant Corynebacterium striatum bacteremia: first case in Korea. Ann Lab Med. 2015;35:472–3.DOIPubMedGoogle Scholar
  13. Campanile  F, Carretto  E, Barbarini  D, Grigis  A, Falcone  M, Goglio  A, Clonal multidrug-resistant Corynebacterium striatum strains, Italy. Emerg Infect Dis. 2009;15:75–8.DOIPubMedGoogle Scholar
  14. Werth  BJ, Hahn  WO, Butler-Wu  SM, Rakita  RM. Emergence of high-level daptomycin resistance in Corynebacterium striatum in two patients with left ventricular assist device infections. Microb Drug Resist. 2016;22:233–7.DOIPubMedGoogle Scholar
  15. Verroken  A, Bauraing  C, Deplano  A, Bogaerts  P, Huang  D, Wauters  G, Epidemiological investigation of a nosocomial outbreak of multidrug-resistant Corynebacterium striatum at one Belgian university hospital. Clin Microbiol Infect. 2014;20:44–50.DOIPubMedGoogle Scholar
  16. Tran  TT, Jaijakul  S, Lewis  CT, Diaz  L, Panesso  D, Kaplan  HB, Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother. 2012;56:3461–4.DOIPubMedGoogle Scholar
  17. Bernard  K, Pacheco  AL. In vitro activity of 22 antimicrobial agents against Corynebacterium and Microbacterium species referred to the Canadian National Microbiology Laboratory. Clin Microbiol Newsl. 2015;37:187–98 .DOIGoogle Scholar
  18. Hudspeth  MK, Hunt Gerardo  S, Citron  DM, Goldstein  EJ. Evaluation of the RapID CB Plus system for identification of Corynebacterium species and other gram-positive rods. J Clin Microbiol. 1998;36:543–7.PubMedGoogle Scholar
  19. Suwantarat  N, Weik  C, Romagnoli  M, Ellis  BC, Kwiatkowski  N, Carroll  KC. Practical utility and accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Corynebacterium species and other medically relevant Coryneform-like bacteria. Am J Clin Pathol. 2016;145:22–8.DOIPubMedGoogle Scholar
  20. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; 2nd edition (M45–A2). Wayne (PA): The Institute; 2010.
  21. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; 3rd edition (M45–ED3). Wayne (PA): The Institute; 2015.
  22. National Cancer Institute Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE) 2006 Aug 9 [cited 2016 Aug 12]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
  23. Otsuka  Y, Ohkusu  K, Kawamura  Y, Baba  S, Ezaki  T, Kimura  S. Emergence of multidrug-resistant Corynebacterium striatum as a nosocomial pathogen in long-term hospitalized patients with underlying diseases. Diagn Microbiol Infect Dis. 2006;54:109–14.DOIPubMedGoogle Scholar
  24. Watkins  DA, Chahine  A, Creger  RJ, Jacobs  MR, Lazarus  HM. Corynebacterium striatum: a diphtheroid with pathogenic potential. Clin Infect Dis. 1993;17:21–5.DOIPubMedGoogle Scholar
  25. McElvania TeKippe  E, Thomas  BS, Ewald  GA, Lawrence  SJ, Burnham  C-AD. Rapid emergence of daptomycin resistance in clinical isolates of Corynebacterium striatum… a cautionary tale. Eur J Clin Microbiol Infect Dis. 2014;33:2199–205.DOIPubMedGoogle Scholar
  26. Lee  PP, Ferguson  DA Jr, Sarubbi  FA. Corynebacterium striatum: an underappreciated community and nosocomial pathogen. J Infect. 2005;50:338–43.DOIPubMedGoogle Scholar
  27. Nhan  T-X, Parienti  J-J, Badiou  G, Leclercq  R, Cattoir  V. Microbiological investigation and clinical significance of Corynebacterium spp. in respiratory specimens. Diagn Microbiol Infect Dis. 2012;74:236–41.DOIPubMedGoogle Scholar
  28. Gomila  M, Renom  F, Gallegos  MC, Garau  M, Guerrero  D, Soriano  JB, Identification and diversity of multiresistant Corynebacterium striatum clinical isolates by MALDI-TOF mass spectrometry and by a multigene sequencing approach. BMC Microbiol. 2012;12:52.DOIPubMedGoogle Scholar
  29. Osmon  DR, Berbari  EF, Berendt  AR, Lew  D, Zimmerli  W, Steckelberg  JM, ; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1–25.DOIPubMedGoogle Scholar
  30. Barr  DA, Semple  L, Seaton  RA. Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2012;31:2611–9.DOIPubMedGoogle Scholar
  31. Stephens  JM, Gao  X, Patel  DA, Verheggen  BG, Shelbaya  A, Haider  S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013;5:447–57.PubMedGoogle Scholar
  32. Morata  L, Tornero  E, Martínez-Pastor  JC, García-Ramiro  S, Mensa  J, Soriano  A. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother. 2014;69(Suppl 1):i47–52.DOIPubMedGoogle Scholar
  33. Tang  S, Yao  L, Hao  X, Zhang  X, Liu  G, Liu  X, Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45:161–70.DOIPubMedGoogle Scholar

Main Article

1Current affiliation: University of Southern California, Los Angeles, California, USA.

Page created: October 12, 2016
Page updated: October 17, 2016
Page reviewed: October 17, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external